Moreover, in cancer patients diagnosed with painful neuropathy as a side effect of the drug Bortezomib, NLRP3 has been found to be overexpressed as a consequence of acetylation of histone H3 and H4 in the NLRP3 promoter region [157], thus driving the disease. The gene discussed is NLRP3; the disease is cancer.